Archive · 11 Aug 2026
Bombay HC rebukes Maharashtra FDA over Cadila drug sale halt
A company called Cadila Pharmaceuticals makes medicines that people need.
A government group called the Maharashtra FDA checks that medicines are safe, and it told Cadila to stop selling some of its medicines and took away its stock.
Cadila thought that was unfair and asked an important court, the Bombay High Court, for help.
The court said the FDA was only showing off its power instead of using it wisely, and that it was like using a big sword to kill a tiny mosquito.
A judge said the FDA behaved like someone from the Wild West who shoots first and asks questions later.
Because of the stop order, patients could not get some medicines for 20 days, and by the time of the court hearing it had been 32 days.
The FDA explained that it acted because medicines with different ingredients had similar packaging, which could confuse patients.
After the court spoke, the FDA promised to cancel the stop-sale order and follow proper steps next time.
Now the company will get a chance to explain itself before any new action is taken.
The Bombay High Court granted relief to Cadila Pharmaceuticals Ltd against the Maharashtra FDA's stop-sale orders and seizure of stock worth Rs 2.45 crore.
The court said the FDA was 'displaying its powers' and using a 'sword to kill a mosquito,' warning it could impose heavy costs.
The bench remarked that 'shooting first and asking questions later' is a rule of the Wild West that does not apply in the arena of law.
The FDA justified its action, alleging similar branding of medicines with different active pharmaceutical ingredients (ranitidine and famotidine) risked medication errors.
The FDA assured revocation of the stop-sale orders and said it would issue show-cause notices and grant a hearing before passing any reasoned order; the court disposed of the petition.
- Who
- Cadila Pharmaceuticals Ltd; the Bombay High Court bench of Acting Chief Justice Ravindra V Ghuge and Justice Gautam A Ankhad; the Maharashtra FDA led by Tukaram Mundhe.
- What
- The Bombay High Court granted relief to Cadila against the Maharashtra FDA's stop-sale orders and seizure of stock worth Rs 2.45 crore, rebuking the regulator for 'displaying its powers' and acting without giving the company a prior hearing.
- When
- Tuesday, August 11, 2026; the affected medicines had been unavailable for 20 days, and effectively 32 days, by the time of the hearing.
- Where
- Bombay High Court, Mumbai, Maharashtra, India.
- Why
- The FDA stopped sales alleging that similar branding of medicines with different active ingredients risked medication errors, while the court said patients were deprived of the medicines without proper process.
Court and Company View
Regulator View
Stopping sales without a prior hearing
Court and Company View
The FDA acted arbitrarily by stopping sales and seizing stock before hearing the company, 'shooting first and asking questions later,' which deprived patients of needed medicines for up to 32 days without due process.
Regulator View
The action was a preventive measure, not high-handed, because Cadila's medicines had similar branding despite different active pharmaceutical ingredients (ranitidine and famotidine), which risked medication errors and patient safety.
How the FDA should exercise its regulatory power
Court and Company View
The FDA keeps taking drastic actions against hotels, restaurants and companies, using a 'sword to kill a mosquito'; it should act systematically, judiciously and only after hearing those affected, and the court warned it may impose heavy costs.
Regulator View
The FDA's enforcement actions are needed to crack down on rule violations, and the same bench has lauded the regulator's crackdown against violations of the rules.
- Company
- Cadila Pharmaceuticals Ltd
- Regulator
- Maharashtra Food and Drug Administration (FDA)
- FDA Head
- Tukaram Mundhe (IAS officer appointed at its helm in May)
- Court Bench
- Acting Chief Justice Ravindra V Ghuge and Justice Gautam A Ankhad
- Stock Seized
- Rs 2.45 crore
- Medicines Affected
- Aciloc 150, Aciloc 150 Plus, Aciloc 300, Aciloc 300 Plus
- Drug Unavailability
- 20 days; effectively 32 days at the time of hearing
- Outcome
- FDA to revoke stop-sale orders, issue show-cause notices and grant a hearing before a reasoned order
Sources
Bombay HC pulls up Maharashtra FDA over Cadila drug ban, says powers must be used judiciously
Use power judiciously, not like a sword to kill a mosquito: HC to FDA; warns of imposing heavy cost
Cadila drugs sale: Bombay HC pulls up food safety body for ‘drastic actions’, urges judicious use of power
Bombay HC Raps Maharashtra FDA For 'Displaying Its Powers', Says Drastic Action Must Be Exercised Judiciously
